Page 4 - ஐபோன் சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐபோன் சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐபோன் சிகிச்சை Today - Breaking & Trending Today

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Toronto, Ontario (Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one . ....

United States , Anne Donohoe , Graham Simmonds , Phil Carlson , Aion Therapeutic Inc , Strategic Communications , Ai Pharmaceuticals Jamaica , Newsfile Corp , Canadian Securities Exchange , Common Share Of The Company , Common Share , Each Warrant , Expiry Date , Common Shares , Canadian Securities , Each Broker Warrant , Multilateral Instrument , Minority Securityholders , Special Transactions , United States Securities Act , Jamaica Limited , Aion Therapeutic , Aion Therapeutic Inc , The Company , Common Share , Aion Therapeutic ,

Apollon Formularies (AQSE:APOL) | RNS | Apollon Formularies - Combined Formulations Kill Breast Cancer Cells


Breast Cancer Cells Through Multiple Pathways
 
LONDON/TORONTO, Apollon Formularies plc (AQSE: APOL, Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION, Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
 
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamaica Limited ( Apollon Jamaica ), and the medic ....

United States , United Kingdom , City Of , Herberta Fritsche , Graham Simmonds , Trastuzumab Herceptin , Stephend Barnhill , Megan Ray , Paul Burke , Tim Blythe , Stene Jacobs , Aion Therapeutic Inc , Apollon Formularies Jamaica , Doc Place International Inc , Md Anderson Cancer Center , Research Development , Trefis Team , Ai Pharmaceuticals Jamaica , Laboratory Medicine , University Of Texas , Decision Resources Group , Ai Pharmaceutical Limited Pharma , Canadian Securities Exchange , Handbook Of Cannabis Oxford University , Apollon Formularies Jamaica Limited , Cannabis Licensing Authority ,

Combined Apollon and Aion Formulations Kill Breast Cancer Cells [...] | Comunicati stampa CataniaOggi


18 maggio 2021 17:32
Fonte: Adnkronos
#salute-e-benessere
LONDON and TORONTO, May 18, 2021 /PRNewswire/  Apollon Formularies plc (AQSE: APOL) ( Apollon or the  Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamai ....

United States , United Kingdom , City Of , Herberta Fritsche , Graham Simmonds , Trastuzumab Herceptin , Stephend Barnhill , Paul Burke , Megan Ray , Tim Blythe , Stene Jacobs , Ai Pharmaceuticals Jamaica Limited Pharma , Aion Therapeutic Inc , Apollon Formularies Jamaica , Doc Place International Inc , Md Anderson Cancer Center , Research Development , Ai Pharmaceuticals Jamaica , Laboratory Medicine , University Of Texas , Decision Resources Group , Canadian Securities Exchange , Apollon Formularies Jamaica Limited , Cannabis Licensing Authority , Aquis Stock Exchange , Peterhouse Capital Limited Corporate Adviser ,